GlassScriptPhysician profile
Amanda Decoursey
NPI 1417552613
$3,647.55
in general payments reported to CMS, 2019-2025
26 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,980 · 2022: $738 · 2023: $393 · 2024: $359 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $929.81 | 2021 | |
| Medtronic, INC. | $747.48 | 2021 | |
| Abbvie INC. | $452.25 | 2021-2025 | |
| Lilly USA, LLC | $233.90 | 2021-2025 | Mounjaro |
| Novo Nordisk INC | $233.24 | 2021-2024 | Rybelsus, Ozempic |
| Indivior INC. | $152.12 | 2021-2024 | Sublocade |
| Exact Sciences Corporation | $124.37 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $112.09 | 2022-2023 | Rexulti |
| Alkermes, INC. | $108.68 | 2021-2023 | Vivitrol |
| Lundbeck LLC | $61.00 | 2022-2023 | Rexulti |
| Pfizer INC. | $52.51 | 2023-2025 | |
| Gilead Sciences, INC. | $52.08 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $48.03 | 2022 | |
| Corcept Therapeutics | $45.79 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $44.63 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $29.31 | 2023 | Stelara |
| Xeris Pharmaceuticals, INC. | $27.51 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $27.43 | 2021-2022 | |
| Amarin Pharma, INC. | $26.80 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.24 | 2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.43 | 2022 | |
| Hologic Sales and Service, LLC | $21.02 | 2021 | |
| Orexo US, INC. | $20.76 | 2023 | |
| Astellas Pharma US INC | $20.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.38 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Decoursey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.